Hot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC

Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023...

Rosalyn Juergens, MD, PhD - Why Precision Matters in NSCLC: Challenges and Solutions for Targeting Rare Oncogenic Driver Mutations in the Canadian Landscape...

Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations...

Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD...

Perry Elliott, MD, FRCP - Continuing Our Conversation in HCM: Compelling Questions and Evolving Considerations...

Walter Chow, BScPhm, MD - Better Outcomes for Your Patients Living With Obesity: Practical Management Strategies for Primary Care...

Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers...

Peter J. Lin, MD, CCFP - Severe Uncontrolled Versus Difficult-to-Treat Asthma: Strategies for Detection, Differentiation, and Referral...

Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?...